CONCORDBIO

Concord Biotech Share Price

₹2,165.20 -23.95 (-1.09%)

28 Dec, 2024 01:54

SIP TrendupStart SIP in CONCORDBIO

Start SIP

Performance

  • Low
  • ₹2,148
  • High
  • ₹2,208
  • 52 Week Low
  • ₹1,327
  • 52 Week High
  • ₹2,664
  • Open Price₹2,203
  • Previous Close₹2,189
  • Volume41,423

Investment Returns

  • Over 1 Month + 4.46%
  • Over 3 Month + 1.57%
  • Over 6 Month + 44.24%
  • Over 1 Year + 43.76%
SIP Lightning

Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!

Invest Now

Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 69.1
  • PEG Ratio
  • 8.9
  • Market Cap Cr
  • 22,652
  • P/B Ratio
  • 14.8
  • Average True Range
  • 81.46
  • EPS
  • 31.35
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 44.37
  • RSI
  • 57.27
  • MFI
  • 55

Concord Biotech Financials

Concord Biotech Technicals

EMA & SMA

Current Price
₹2,165.20
-23.95 (-1.09%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹2,119.25
  • 50 Day
  • ₹2,040.14
  • 100 Day
  • ₹1,936.10
  • 200 Day
  • ₹1,767.28

Resistance and Support

2173.67 Pivot Speed
  • R3 2,259.13
  • R2 2,233.47
  • R1 2,199.33
  • S1 2,139.53
  • S2 2,113.87
  • S3 2,079.73

What's your outlook on Concord Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,085.75 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 40% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 24% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 61 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-09 Quarterly Results
2024-05-23 Audited Results & Dividend
2024-02-08 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2024-06-22 FINAL Rs.8.75 per share(875%)Dividend

Concord Biotech F&O

Concord Biotech Shareholding Pattern

44.08%
4.97%
4.3%
8.1%
7.33%
31.22%

About Concord Biotech

Concord Biotech Ltd. is leading biotechnology company in India, specializing in development & manufacturing of fermentation based biopharmaceuticals. Established in 2000, company has grown to become significant player in global biotech industry, with strong focus on immunosuppressants, oncology, & nephrology products. Concord Biotech's state of the art manufacturing facilities are designed to meet international quality standards, enabling company to supply its products to over 70 countries worldwide. company's dedication to innovation, research, & development has made it trusted partner in global healthcare industry.

diversified clientele: 200 clients in more than 70 countries use company's API & formulation solutions. long-term supply agreements with these clients accounted for 14.06%, 12.45%, & 12.56% of their revenues in FY21, FY22, & FY23.
R&D: Concord maintains specialized R&D facilities for formulations & APIs in Dholka & Valthera. Both have Indian DSIR's approval. Their R&D units employed 148 people as of March 31, 2022, making up 11.99% of their total number of permanent employees.

Domestic Presence: They sell range of 27 products in India, including immunosuppressants, nephrology medications, & anti-infective medications used in critical care. In India, they are present in 20 states & 5 union territories.

View More
  • NSE Symbol
  • CONCORDBIO
  • BSE Symbol
  • 543960
  • Chairman & Managing Director
  • Mr. Sudhir Vaid
  • ISIN
  • INE338H01029

Similar Stocks to Concord Biotech

Concord Biotech FAQs

Concord Biotech share price is ₹2,165 As on 28 December, 2024 | 01:40

The Market Cap of Concord Biotech is ₹22651.5 Cr As on 28 December, 2024 | 01:40

The P/E ratio of Concord Biotech is 69.1 As on 28 December, 2024 | 01:40

The PB ratio of Concord Biotech is 14.8 As on 28 December, 2024 | 01:40

Consider company's product pipeline & growth prospects in biotech industry before investing.
 

Key metrics include revenue from key therapeutic areas, R&D investment, & profit margins.

Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Concord Biotech share, you can then put order as you prefer.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23